Modified mRNA-Mediated CCN5 Gene Transfer Ameliorates Cardiac Dysfunction and Fibrosis without Adverse Structural Remodeling

Int J Mol Sci. 2024 Jun 6;25(11):6262. doi: 10.3390/ijms25116262.

Abstract

Modified mRNAs (modRNAs) are an emerging delivery method for gene therapy. The success of modRNA-based COVID-19 vaccines has demonstrated that modRNA is a safe and effective therapeutic tool. Moreover, modRNA has the potential to treat various human diseases, including cardiac dysfunction. Acute myocardial infarction (MI) is a major cardiac disorder that currently lacks curative treatment options, and MI is commonly accompanied by fibrosis and impaired cardiac function. Our group previously demonstrated that the matricellular protein CCN5 inhibits cardiac fibrosis (CF) and mitigates cardiac dysfunction. However, it remains unclear whether early intervention of CF under stress conditions is beneficial or more detrimental due to potential adverse effects such as left ventricular (LV) rupture. We hypothesized that CCN5 would alleviate the adverse effects of myocardial infarction (MI) through its anti-fibrotic properties under stress conditions. To induce the rapid expression of CCN5, ModRNA-CCN5 was synthesized and administrated directly into the myocardium in a mouse MI model. To evaluate CCN5 activity, we established two independent experimental schemes: (1) preventive intervention and (2) therapeutic intervention. Functional analyses, including echocardiography and magnetic resonance imaging (MRI), along with molecular assays, demonstrated that modRNA-mediated CCN5 gene transfer significantly attenuated cardiac fibrosis and improved cardiac function in both preventive and therapeutic models, without causing left ventricular rupture or any adverse cardiac remodeling. In conclusion, early intervention in CF by ModRNA-CCN5 gene transfer is an efficient and safe therapeutic modality for treating MI-induced heart failure.

Keywords: CCN5; cardiac fibrosis; heart failure (HF); left ventricular rupture; modified mRNA (modRNA); myocardial infarction (MI).

MeSH terms

  • Animals
  • CCN Intercellular Signaling Proteins* / genetics
  • CCN Intercellular Signaling Proteins* / metabolism
  • Disease Models, Animal
  • Fibrosis*
  • Gene Transfer Techniques
  • Genetic Therapy* / methods
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Myocardial Infarction* / genetics
  • Myocardial Infarction* / metabolism
  • Myocardial Infarction* / pathology
  • Myocardial Infarction* / therapy
  • Myocardium / metabolism
  • Myocardium / pathology
  • RNA, Messenger* / genetics
  • RNA, Messenger* / metabolism
  • Ventricular Remodeling / genetics

Substances

  • CCN Intercellular Signaling Proteins
  • RNA, Messenger
  • WISP-2 protein, mouse